Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Oxethazaine
Therapeutic Area : Gastroenterology
Study Phase : Phase III
Sponsor : Trium Analysis Online GmbH | Icon Plc | Clinipace Worldwide
Deal Size : Inapplicable
Deal Type : Inapplicable
Tepilta® Versus Oxetacaine, Antacids and Placebo
Details : Oxetacaine is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Esophagitis.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 18, 2011
Lead Product(s) : Oxethazaine
Therapeutic Area : Gastroenterology
Highest Development Status : Phase III
Sponsor : Trium Analysis Online GmbH | Icon Plc | Clinipace Worldwide
Deal Size : Inapplicable
Deal Type : Inapplicable